HandiHaler: Clinical Trials

8 completed. 4 Phase 4, 2 Phase 3, 1 Not applicable, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 4	4	Completed 4
Phase 3	2	Completed 2
Not applicable	1	Completed 1
Phase 2	1	Completed 1

Follow HandiHaler: new trials by email Literature Review of HandiHaler trials Research Report on HandiHaler

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI - Pulmonary Disease, Chronic Obstructive	Phase 4	Completed	GlaxoSmithKline	732	2018-06-25	2020-10-28
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI - Pulmonary Disease, Chronic Obstructive	Phase 4	Completed	GlaxoSmithKline	729	2018-06-25	2020-10-28
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) FF/UMEC/VI, Tiotropium, Albuterol/salbutamol - Pulmonary Disease, Chronic Obstructive	Phase 4	Completed	GlaxoSmithKline	800	2018-03-29	2021-07-15
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices ELLIPTA, DISKUS/ACCUHALER, MDI - Pulmonary Disease, Chronic Obstructive	Phase 4	Completed	GlaxoSmithKline	569	2014-08-28	2017-05-23
Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients tiotropium, Handihaler, Respimat - Chronic Obstructive Pulmonary Disease	Not applicable	Completed	University of Crete	200	2010-03-01	2017-03-30
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD Tiotropium, HandiHaler, Respimat SMI - Pulmonary Disease, Chronic Obstructive	Phase 3	Completed	Boehringer Ingelheim	131	2002-11-26	2023-12-01
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD) Tiotropium, Respimat SMI, HandiHaler - Pulmonary Disease, Chronic Obstructive	Phase 3	Completed	Boehringer Ingelheim	76	2002-08-01	2013-11-01
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) Tiotropium 0.625 mcg/puff, Tiotropium 1.25 mcg/puff, Tiotropium 2.5 mcg/puff - Pulmonary Disease, Chronic Obstructive	Phase 2	Completed	Boehringer Ingelheim	202	1998-03-01	2025-01-31

Conditions studied

Pulmonary Disease, Chronic Obstructive (8)  ·  Sleep Initiation and Maintenance Disorders (1)

Sponsors

GlaxoSmithKline (4)  ·  Boehringer Ingelheim (3)  ·  University of Crete (1)

Countries

United States (4)  ·  Netherlands (3)  ·  Czechia (2)  ·  Germany (2)  ·  Belgium (1)  ·  Canada (1)  ·  Poland (1)  ·  Russia (1)  ·  United Kingdom (1)

Top investigators

Sophia E Schiza, MD, PhD (1)

Results publications

PMID 27883002

NIH funding

2017 (3)